CLINICAL USE


Treatment of obesity for patients who have not responded to appropriate weight reducing methods

DOSE IN NORMAL RENAL FUNCTION

10–15 mg daily

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :334.3
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :97
  • %Excreted unchanged in urine &nbsp &nbsp : Only inactive metabolites

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :No data

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :14–16

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function. Use with caution
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function. Use with caution
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function. Use with caution

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR <10 mL/min

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in GFR <10 mL/min
  • HDF/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL/min
  • CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Antidepressants: increased risk of CNS toxicity; avoid concomitant administration with MAOIs and moclobemide – avoid for at least 2 weeks after stopping sibutramine; increased CNS toxicity with noradrenaline re-uptake inhibitors, tricyclics, SSRIs, mirtazapine and tryptophan – avoid concomitant use with tryptophan
  • Antipsychotics: increased risk of CNS toxicity – avoid concomitant useAvoid use with drugs which increase heart rate or blood pressure

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Do not use in patients with uncontrolled hypertension, i.e. BP >145/90 mmHgInitiation of therapy is associated with a mean increase in resting systolic and diastolic BP of 2–3 mmHg
    Tags:

    • Related News

    sotalol hydrochloride.txt

    tazocin.txt